ReviewFrontiers in immunology2018
Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Construction of lactate-myeloid-related prognostic risk model and prediction of immune-excluded microenvironment in gastric cancer via integrated scRNA-Seq and bulk RNA-Seq.Translational cancer research · 2026Article
- Perturbed CD81 in lung-cancer-derived extracellular vesicles modifies its function in cancer pathophysiology.Molecular therapy. Oncology · 2025Article
- An overview on the interaction between non-coding RNAs and CTLA-4 gene in human diseases.Medical oncology (Northwood, London, England) · 2024Review
- The Inhibitory Effect and Mechanism of the Histidine-Rich Peptide rAj-HRP fromMolecules (Basel, Switzerland) · 2024Article
- New insights into the role of tetraspanin 6, 7, and 8 in physiology and pathology.Cancer medicine · 2024Review
- The Multifunctional Protein Syntenin-1: Regulator of Exosome Biogenesis, Cellular Function, and Tumor Progression.International journal of molecular sciences · 2023Review
- Review
- TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN.Signal transduction and targeted therapy · 2023Article
- Article
- Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37.Nature communications · 2022Article
- Single vesicle analysis of CD47 association with integrins and tetraspanins on extracellular vesicles released by T lymphoblast and prostate carcinoma cells.Journal of extracellular vesicles · 2022Article
- hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration.Journal of immunology research · 2022Article
- Nanotechnology-enhanced immunotherapy for metastatic cancer.Innovation (Cambridge (Mass.)) · 2021Review
- The Role of Melanoma Cell-Derived Exosomes (MTEX) and Photodynamic Therapy (PDT) within a Tumor Microenvironment.International journal of molecular sciences · 2021Review
- [CCL18 Promotes the Invasion of Lung Adenocarcinoma through ANXA2].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.International journal of molecular sciences · 2021Article
- Changes in Exosome Release in Thyroid Cancer Cells after Prolonged Exposure to Real Microgravity in Space.International journal of molecular sciences · 2021Article
- Cell Adhesion Molecules in Plasticity and Metastasis.Molecular cancer research : MCR · 2021Review
- AEBP1 Is One of the Epithelial-Mesenchymal Transition Regulatory Genes in Colon Adenocarcinoma.BioMed research international · 2021Article
- Open conformation of tetraspanins shapes interaction partner networks on cell membranes.The EMBO journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is the ultimate consequence of cancer progression and the cause of patients' death across different cancer types. Patients with initial diagnosis of distant disease have a worst 5-year survival compared to patients with localized disease. Therapies that target primary tumors fail to eradicate distant dissemination of cancer. Recently, immunotherapies have improved the survival of patients with metastatic disease, such as melanoma and lung cancer. However, only a fraction of patients responds to immunotherapy modalities that target the host immune system. The need to identify new druggable targets that inhibit or prevent metastasis is, therefore, much needed. Tetraspanins have emerged as key players in regulating cell migration, invasion, and metastasis. By serving as molecular adaptors that cluster adhesion receptors, signaling molecules, and cell surface receptors; tetraspanins are involved in all steps of the metastatic cascade. They regulate cell proliferation, participate in EMT transition, modulate integrin-mediated cell adhesion, and participate in angiogenesis and invasion processes. Tetraspanins have also been shown to modulate metastasis indirectly through exosomes and by regulating cellular interactions in the immune system. Importantly, targeting individual tetraspanin with antibodies has impacted tumor progression. This review will focus on the contribution of tetraspanins to the metastatic process and their potential as therapeutic tumor targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.